CD223 Antibody, anti-human, REAfinity™
Synonyms: LAG-3, Protein FDC, LAG3
RECOMBINANT EXTENDED VALIDATION
Bioz Star94/100 Bioz rating
97 Citations4 Images
Clone:
REA351 | 17B4
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MICS, IF, IHC, MC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CD223 Antibody, anti-human, REAfinity™

Flow cytometry applications
APC
APC-Vio 770
Biotin
PE
PE-Vio 615
PE-Vio 670
PE-Vio 770
Vio Bright B515
Vio Bright V423
Vio Bright V600
VioBlue
Recommended dilution:
1:50
Remark:
The antibody is suited for staining of formaldehyde-fixed cells.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-119-666, 130-119-567
Description:
Human peripheral blood mononuclear cells (PBMCs) were either left unstimulated (left images) or stimulated with CD3 and CD28 antibodies for 3 days. Cells were then stained with CD223 antibodies as well as with CD8 antibodies and analyzed by flow cytometry using the MACSQuant® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence.

Application imageView details view details

Application imageView details view details
MICS (MACSima Imaging Cyclic Staining) applications
PE
Fixation:
frozen – Acetone
Species tested:
human
Tissue used:
tonsil
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
PE
Used products:
130-140-157
Testing grade:
Fixation:
FFPE
Species tested:
human
Tissue used:
tonsil
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
PE
Used products:
130-140-157
Testing grade:
Description:
Immunofluorescence analysis of a formalin-fixed, paraffin embedded (FFPE) human tonsil. Before staining, antigens were retrieved using heat-induced epitope retrieval (HIER) at pH 9. The section was stained using CD223 Antibody, anti-human, PE (green) for 10 min at room temperature. Nuclei were visualized with Hoechst™ (blue). Scale bar: 30 µm.

Application image
Mass cytometry applications
pure
Conjugate:
pure
Used products:
130-124-529
Extended validation for CD223 Antibody, anti-human, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA351
T47-530
partial
3DS223H
++
11C3C65
low
7H2C65
partial
17B4
high

Cells were incubated with an excess of purified unconjugated CD223 (REA351) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Sensitivity
Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image

Flow cytometric comparison of different clones for CD223. Human peripheral blood mononuclear cells (PBMCs) stimulated with CD3/CD28 antibodies (T Cell TransAct™) for 3 days were stained with CD223 antibodies and with a suitable counterstaining. As a control, CD223 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Extended-Validation detailed information image

Flow cytometric comparison of different clones for CD223 shown as brightest.

Fixation data

To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.

No fixation
Extended-Validation detailed information image
Post fixation
Extended-Validation detailed information image

Comparison of staining pattern on non-fixed and fixed cells using CD223 (REA351). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD223 Antibody, anti-human, REAfinity™
Overview

Clone REA351 recognizes the human CD223 antigen, a single-pass type I membrane protein also known as lymphocyte activation gene 3 protein (LAG-3). CD223 is a CD4 homolog with four extracellular Ig superfamily domains. Similar to CD4, CD223 oligomerizes at the surfaces of T cells and binds to MHC II on antigen presenting cells but with significantly higher affinity than CD4. CD223 is expressed on activated CD4+ and CD8+ T lymphocytes where it associates with the CD3–TCR complex at the cell surface and negatively regulates signal transduction. As a consequence, it negatively regulates T cell proliferation, function, and homeostasis. There is also increasing evidence of its involvement in regulatory function of tumor-infiltrated T cells in cancer, such as in Hodgkin’s lymphomas and in prostate cancer. CD223 is also expressed on activated NK cells, B cells, and plasmacytoid dendritic cells.

Additional information: Clone REA351 displays negligible binding to Fc receptors.

Alternative names

LAG-3, Protein FDC, LAG3

Detailed product information

Technical specifications

Clone
REA351
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
CD223
Molecular mass of antigen [kDa]
54
Distribution of antigen
T cells, lymphocytes
Entrez Gene ID
RRID
AB_2801747, AB_2889510, AB_2819662, AB_2904844, AB_2928330, AB_2904843, AB_2928331, AB_2751648, AB_2904845, AB_2889511, AB_2801740, AB_2751602, AB_2733934, AB_2733935, AB_2904842, AB_2784079, AB_2784077, AB_2784078, AB_2784076

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD223 Antibody, anti-human, REAfinity™
Documents and Protocols
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

You have previously chosen International as your location.
What do you want to do?